BDBM354268 (2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl)-1H-indazol-1- yl)acetyl)-N-(6- bromopyridin-2-yl)-4- fluoropyrrolidine-2- carboxamide::US10287301, Compound 165::US10822352, Comp No. 165::US9796741, cmp No. 165

SMILES CC(=O)c1nn(CC(=O)N2C[C@H](F)C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccc(cc12)-c1cnc(C)nc1

InChI Key InChIKey=PIBARDGJJAGJAJ-NQIIRXRSSA-N

Data  6 IC50  1 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 354268   

TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataKd: <1nMAssay Description:Binding affinity to human factor D by SPR analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50:  4nMAssay Description:Inhibition of factor D in human serum assessed as decrease in alternative pathway of complement-mediated hemolysis of PNH erythrocytesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50:  4nMAssay Description:Inhibition of factor D in human serum assessed as decrease in C3 deposition on PNH erythrocytesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354268((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50:  15nMAssay Description:Inhibition of human factor D using C3b as substrate assessed as decrease in formation of factor B cleavage product BaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed